Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of ascending doses of ION582 administered intrathecally in participants with Angelman syndrome.

Clinical Trial Description

This is a Phase 1-2a, open-label dose-escalation study of ION582 enrolling up to approximately 44 participants. Following a screening period of up to 4 weeks, eligible participants will receive intrathecal (IT) injections of ION582. Participants will be followed for up to 32 weeks after dosing. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05127226
Study type Interventional
Source Ionis Pharmaceuticals, Inc.
Contact Ionis Pharmaceuticals
Phone 800-679-4747
Email [email protected]
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date November 2021
Completion date December 2023

See also
  Status Clinical Trial Phase
Completed NCT00004351 - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes N/A
Not yet recruiting NCT05011851 - An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome Phase 2
Completed NCT03235037 - Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome N/A
Recruiting NCT05100810 - Angelman Syndrome Natural History Study-FAST UK
Completed NCT03644693 - Nutritional Formulation for Angelman Syndrome N/A
Completed NCT03358823 - Study on the Brain Network of Angelman Syndrome
Not yet recruiting NCT04768803 - Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity
Completed NCT02670694 - Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW N/A
Completed NCT00348933 - Dietary Supplements for the Treatment of Angelman Syndrome N/A
Completed NCT02996305 - A Study in Adults and Adolescents With Angelman Syndrome Phase 2
Completed NCT02056665 - Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome Phase 2
Completed NCT01281475 - A Trial of Levodopa in Angelman Syndrome Phase 2/Phase 3
Completed NCT00829439 - Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome Phase 1
Recruiting NCT03882918 - An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome Phase 2
Recruiting NCT04259281 - A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome Phase 1/Phase 2
Completed NCT00296764 - Characterization of Angelman Syndrome
Active, not recruiting NCT03650569 - Angelman Syndrome Italian Registry
Recruiting NCT04103333 - Angelman Syndrome (AS) Biomarker Study Early Phase 1
Recruiting NCT04428281 - A Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of RO7248824 In Participants With Angelman Syndrome Phase 1
Recruiting NCT04507997 - Angelman Syndrome Natural History Study